NEUREN PHARMACEUTICALS LIMITED

ASX: NEU

Sector: Sector:Health Care
Industry group: Industry:Pharmaceuticals, Biotechnology & Life Sciences

NEU News & Analysis

NEUHealth CareCompany Update29 Sept 202629 September 2026· 2 min read

Neuren Pharmaceuticals (ASX: NEU) Extends Trofinetide US Patent Protection to 2041

Neuren Pharmaceuticals expects US patent protection for trofinetide to extend by almost five years to March 2041 following allowance of a weight-banded dosing patent application.

Latest NEU ASX Announcements

29 Sept 2026 · 10:34 amCompany Update
Trofinetide US patent protections extended to March 2041
29 Sept 202610:34 amTrofinetide US patent protections extended to March 2041Company Update
29 Sept 2026 · 9:59 amTrading Halt / Suspension
Pause in Trading
29 Sept 20269:59 amPause in TradingTrading Halt / Suspension
18 Sept 2026 · 4:12 pmDividends & Distributions
Update - Dividend/Distribution - NEU
18 Sept 20264:12 pmUpdate - Dividend/Distribution - NEUDividends & Distributions
2 Sept 2026 · 8:50 amPresentations
Corporate Presentation, 2 September 2026
2 Sept 20268:50 amCorporate Presentation, 2 September 2026Presentations
26 Aug 2026 · 4:56 pmDividends & Distributions
Dividend/Distribution - NEU
26 Aug 20264:56 pmDividend/Distribution - NEUDividends & Distributions
26 Aug 2026 · 10:40 amFinancial Results
Investor presentation, 26 August 2026
26 Aug 202610:40 amInvestor presentation, 26 August 2026Financial Results
26 Aug 2026 · 9:47 amFinancial Results
Growing royalty anchors Neuren first ever dividend program
26 Aug 20269:47 amGrowing royalty anchors Neuren first ever dividend programFinancial Results
26 Aug 2026 · 9:25 amFinancial Results
Half Yearly Report and Accounts
26 Aug 20269:25 amHalf Yearly Report and AccountsFinancial Results
25 Aug 2026 · 8:31 amCompany Update
European Commission grants marketing authorisation for DAYBU
25 Aug 20268:31 amEuropean Commission grants marketing authorisation for DAYBUCompany Update
21 Aug 2026 · 3:19 pmPresentations
Neuren H1 2026 Financial Results Webinar on 26 August 2026
21 Aug 20263:19 pmNeuren H1 2026 Financial Results Webinar on 26 August 2026Presentations
5 Aug 2026 · 9:52 amCompany Update
Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
5 Aug 20269:52 amRecord Q2 DAYBUE net sales of US$125m, CY26 royalty upgradedCompany Update
24 July 2026 · 9:57 amCompany Administration
Neuren highlights participation in PMSF Family Conference
24 July 20269:57 amNeuren highlights participation in PMSF Family ConferenceCompany Administration
29 June 2026 · 7:43 amCompany Update
DAYBU recommended for approval in the European Union
29 June 20267:43 amDAYBU recommended for approval in the European UnionCompany Update
18 June 2026 · 4:49 pmSecurities Administration
Application for quotation of securities - NEU
18 June 20264:49 pmApplication for quotation of securities - NEUSecurities Administration
1 June 2026 · 5:47 pmSecurities Administration
Notification of cessation of securities - NEU
1 June 20265:47 pmNotification of cessation of securities - NEUSecurities Administration

View complete NEU announcement history →

NEUREN PHARMACEUTICALS LIMITED

NEU Share Price

NEU News & Analysis

Neuren Pharmaceuticals (ASX: NEU) Extends Trofinetide US Patent Protection to 2041

Latest NEU ASX Announcements